Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
Trial ID or NCT#
The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy plus the FDA-approved chemotherapy drug temozolomide
A Phase 1-2 Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme
- - Histopathologically confirmed newly diagnosed glioblastoma multiforme. Diagnosis must be made by surgical biopsy or excision - The tumor must be supratentorial in location - The planning target volume (tumor plus margin) must measure ≤ 150 cm^3 in volume - Age ≥ 18 years - Life expectancy of at least 12 weeks - Patient must have adequate organ function to tolerate temozolomide (details in the protocol)
- - Patients who have previously been treated with brain irradiation to the region that would result in overlap of the radiation fields - Tumor foci detected below the tentorium - Multifocal disease or leptomeningeal spread - Prior allergic reaction to the study drugs involved in this protocol - Patients with pacemaker will be allowed to undergo CT instead of MRI - Pediatric patients (age < 18), pregnant women, and nursing patients will be excluded
Contact us to find out if this trial is right for you.
View on ClinicalTrials.gov